Digestive Health

Risankizumab-rzaa is the first and only specific IL-23 inhibitor approved to treat moderately to severely active Crohn disease in adults.

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

Researchers studying the gut microbiome found that fiber supplements of any kind could improve gut health.

Health care professionals need to work closely with patients in understanding polypharmacy and the risk/benefit of pharmacotherapy.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Senokot-S is indicated for constipation relief.

Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.

Submissions are based on 3 phase 3 clinical trials showing that the drug achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment.

NauseaCalm relieves nausea and vomiting to treat the symptoms of upset stomach and the stomach flu.

It’s common practice to recommend heart failure patients follow low sodium diets, but research has shown this type of diet may worsen patient health for certain forms of the condition.

Dupilumab (Dupixent) is the first medicine to improve signs of eosinophilic esophagitis and support weight gain in children ages 1 to 11, for whom there are no currently approved treatments.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.

Risankizumab-rzaa (Skyrizi) is the first and only specific interleukin-23 inhibitor approved for the treatment of adults with moderately to severely active Crohn disease.

These results from 3 separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with ustekinumab (Stelara) were presented at Digestive Disease Week meeting in San Diego, California.

IBS Complete Support helps relieve abdominal pain, bloating, and constipation associated with irritable bowel syndrome.

Pepcid is indicated in adult and pediatric patients 40 kg and above for the treatment of active duodenal ulcer active gastric ulcer.

Gastro-Ease helps maintain a healthy stomach, promoting health and comfort.

The drug is a treatment for individuals who are healing all grades of erosive esophagitis, as a relief of heartburn, and as maintenance of healing all grades of EE and relief of heartburn.

Any antibiotic use was associated with higher rates of IBD, and the risk went up substantially with each course.

Beat the Bloat helps reduce belly bloat caused by digestion woes, gas, and water retention.

Be aware of products containing gluten, nonsteroidal anti-inflammatory drugs, and olmesartan.

Docusate treats occasional constipation by reducing surface tension and emulsification of fecal matter, which allows water to penetrate and mix with and soften stool.

Obeticholic acid (Ocaliva) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

Phazyme is used to treat symptoms of gas, such as belching, bloating, and pressure in the stomach/gut.

A significantly greater proportion or patients treated with either 15 or 30 mg show remission or endoscopic response or remission at week 52 compared with the placebo.

Mesalamine is used to treat and prevent flare-ups of mild to moderately active ulcerative colitis.

Vedolizumab (Entyvio) is indicated for adult patients with moderately to severely active ulcerative colitis and adult patients with moderately to severely active Crohn disease.

Oxy-Powder is designed to clean the digestive tract and oxidize and decrease the amount of impacted fecal matter.

The Voquezna Triple Pak (vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak (vonoprazan, amoxicillin) were previously granted priority review designation by the FDA for H. pylori infection.